Anonymous
Guest
Anonymous
Guest
Really? Who is going to buy a single-product company with generic incursion in the next 15 months? The company line is that their service is "world-class", but most customers can't wait to get anyone to provide them with an equivalent service. They expanded their sales force because it was necessary to attract a new product and to launch Lucassin. Neither has, or will, happen. All it did was downgrade morale with the sales force, twice as many people fighting over the same commission pie.
A CEO with a record of nothing but failure....premie indication NOPE, Lucassin launch NOPE, BPD indication NOPE, much promised B&D acquistions NOPE, seamlessl INOVENT DS launch NOPE, taking the company public NOPE.....
Relying on a pipeline that is tepid at best with and no track record of actually getting a successful FDA approval? Not wise.
Anyone who buys Ikaria is buying it on the hope of a pipeline product and they will be able to get it on the cheap, as with generic erosion Ikaria won't have adequate funding to keep doing R&D on their own.
A CEO with a record of nothing but failure....premie indication NOPE, Lucassin launch NOPE, BPD indication NOPE, much promised B&D acquistions NOPE, seamlessl INOVENT DS launch NOPE, taking the company public NOPE.....
Relying on a pipeline that is tepid at best with and no track record of actually getting a successful FDA approval? Not wise.
Anyone who buys Ikaria is buying it on the hope of a pipeline product and they will be able to get it on the cheap, as with generic erosion Ikaria won't have adequate funding to keep doing R&D on their own.